Comparative cardiometabolic safety and effectiveness of aripiprazole in people with severe mental illness: A target trial emulation
PLOS Medicine · 2025
DOI: 10.1371/journal.pmed.1004520 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS Medicine, 2025. Verfasst von Alvin Richards-Belle und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Psychiatry, University College London, London, United Kingdom. Hauptthemen laut MEDLINE: Aripiprazole, Antipsychotic Agents, Mental Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, UK Research and Innovation, University College London Hospitals Biomedical Research Centre.
Abstract (Originalsprache)
Background
There is limited and conflicting evidence on the comparative cardiometabolic safety and effectiveness of aripiprazole in the management of severe mental illness. We investigated the hypothesis that aripiprazole has a favourable cardiometabolic profile, but similar effectiveness when compared to olanzapine, quetiapine, and risperidone. Methods and findings We conducted an observational emulation of a head-to-head trial of aripiprazole versus olanzapine, quetiapine, and risperidone in UK primary care using data from the Clinical Practice Research Datalink. We included adults diagnosed with severe mental illness (i.e., bipolar disorder, schizophrenia, and other non-organic psychoses) who were prescribed a new antipsychotic between 2005 and 2017, with a 2-year follow-up to 2019. The primary outcome was total cholesterol at 1 year (cardiometabolic safety). The main secondary outcome was psychiatric hospitalisation (effectiveness). Other outcomes included body weight, blood pressure, all-cause discontinuation, and mortality. Analyses adjusted for baseline confounders, including sociodemographics, diagnoses, concomitant medications, and cardiometabolic parameters. We included 26,537 patients (aripiprazole, n = 3,573, olanzapine, n = 8,554, quetiapine, n = 8,289, risperidone, n = 6,121). Median (IQR) age was 53 (42−67) years, 55.4% were female, 82.3% White, and 18.0% were diagnosed with schizophrenia. Patients prescribed aripiprazole had similar total cholesterol levels after 1 year to those prescribed olanzapine (adjusted mean difference [aMD], −0.03, 95% CI, −0.09 to 0.02, p = 0.261), quetiapine (aMD, −0.03, 95% CI, −0.09 to 0.03, p = 0.324), and risperidone (aMD, −0.01, 95% CI, −0.08 to 0.05, p = 0.707). However, there was evidence that patients prescribed aripiprazole had better outcomes on other cardiometabolic parameters, such as body weight and blood pressure, especially compared to olanzapine. After additional adjustment for prior hospitalisation, patients prescribed aripiprazole had similar rates of psychiatric hospitalisation as those prescribed olanzapine (adjusted hazard ratio [aHR], 0.91, 95% CI, 0.82 to 1.01, p = 0.078), quetiapine (aHR, 0.94, 95% CI, 0.85 to 1.04, p = 0.230), or risperidone (aHR, 1.01, 95% CI, 0.91 to 1.12, p = 0.854).
Conclusions
Data from our large, powered, diverse, real-world target trial emulation sample, followed over 2 years, suggest that adults diagnosed with severe mental illness prescribed aripiprazole have similar total cholesterol 1 year after first prescription compared to those prescribed olanzapine, quetiapine, and risperidone. However, patients prescribed aripiprazole had better outcomes on some other cardiometabolic parameters, and there was little evidence of differences in effectiveness. Our findings inform a common clinical dilemma and contribute to the evidence base for real-world clinical decision-making on antipsychotic choice for patients diagnosed with severe mental illness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Psychiatry, University College London, London, United Kingdom.
- Expert by Experience, United Kingdom.
- Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom.
- Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
- Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong.
- Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Pak Shek Kok, Hong Kong.
ORCID-Profile: Alvin Richards-Belle, Naomi Launders, Kenneth K C Man, Neil M Davies, Joseph F Hayes
Förderung
- Wellcome Trust
- UK Research and Innovation
- University College London Hospitals Biomedical Research Centre
- NIHR ARC North Thames
- CW Maplethorpe Fellowship
- European Union Horizon 2020
- National Institute for Health and Care Research
- Hong Kong Research Grant Council
Zitieren
APA
Richards-Belle, A., Launders, N., Hardoon, S., Richards, A., Man, K. K. C., Davies, N. M., Bramon, E., Hayes, J. F., & Osborn, D. P. J. (2025). Comparative cardiometabolic safety and effectiveness of aripiprazole in people with severe mental illness: A target trial emulation. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004520
Vancouver
Richards-Belle A, Launders N, Hardoon S, Richards A, Man KKC, Davies NM, et al. Comparative cardiometabolic safety and effectiveness of aripiprazole in people with severe mental illness: A target trial emulation. PLOS Medicine. 2025. doi:10.1371/journal.pmed.1004520
BibTeX
@article{RichardsBelle2025,
author = {Richards-Belle, Alvin and Launders, Naomi and Hardoon, Sarah and Richards, Al and Man, Kenneth K C and Davies, Neil M and Bramon, Elvira and Hayes, Joseph F and Osborn, David P J},
title = {Comparative cardiometabolic safety and effectiveness of aripiprazole in people with severe mental illness: A target trial emulation},
journal = {PLOS Medicine},
year = {2025},
doi = {10.1371/journal.pmed.1004520}
}
EUVIMED